AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it from ...

After a big investment earmarked for the US last year, AstraZeneca now intends to invest $15 billion in China, reflecting its strategic focus. AZN has meant to expand in the market for some time, most ...

AstraZeneca (AZN) announced on Friday that its antibody therapy, tozorakimab, reached the key goals in two Phase 3 trials for patients with chronic obstructive pulmonary disease, a respiratory disease ...

SHANGHAI, March 19 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Thursday it would build a cell therapy manufacturing and supply base and an innovation centre ‌in Shanghai, aiming to become ...

AstraZeneca AZN1.96%increase; green up pointing triangle shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path ...

AstraZeneca shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path to seek approval from regulators. The U.K.

AstraZeneca AZN3.41%increase; green up pointing triangle said it received European Union approval for its Imfinzi drug as a treatment for early-stage gastric and gastroesophageal cancers, expanding ...

Check out the companies making the biggest moves premarket: AstraZeneca — The pharma giant rose 3% after its experimental drug, tozorakimab, was found to meaningfully reduce flare-ups in cases of ...